Copenhagen, Denmark, 13 May 2026 – FluoGuide A/S ("FluoGuide" or the "Company") is inviting investors to an event on Tuesday, June 2, 2026, where participants will get a close-up look at the company’s technology and clinical applications through a live brain surgery simulation using FluoGuide’s drug candidate FG001.
The attendees will have the opportunity to
- Do a live microscope-based simulation of brain surgery and experience the difference between surgery performed with and without FG001.
- Meet Dr Jane Skjøth-Rasmussen, MD, PhD. neurosurgeon at Rigshospitalet, who leads the Danish clinical trials in brain tumors with FG001 and has performed the highest number of surgeries using FG001 to date.
- Learn about the practical implications of FluoGuide’s: FDA Fast Track designation and IND (Investigational New Drug) clearance for the U.S. market.
- Gain insight into the clinical results for FG001 and upcoming milestones in aggressive brain cancer and head & neck cancer.
Time and Location
- Date: Tuesday, June 2, 2026
- Time: 16:30–18:00 CET
- Location: Titanhus, Titangade 9–13, 2200 Copenhagen.
The invitation (in Danish is enclosed). Registration is required by follow this link (https://fluoguide.com/event/fluoguide-event/)